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$1239: outpatient care). Though the overall predictive
power of the model was low (R2  0.10), the most sig-
nificant predictors of increased total cost were: CGIm-
pression (P  .001), SOFAS (P  .014), ethnicity (P 
.001), and onset age (P  .080). CONCLUSIONS: Inpa-
tient care represents the largest component (42%) of the
total cost of care for patients in this study. Costs are
higher for Caucasian patients, patients with later onset of
disease, and patients with more severe disease measured
by CGImpressions and SOFAS. Whether the use of more
effective medications will decrease hospitalization and to-
tal costs remains to be determined.
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Complete economic evaluations of new antidepressants
should consider the impact of depression on productivity
costs associated with impaired work performance and
other disability as well as on direct medical costs. OB-
JECTIVES: This study compares costs and effectiveness
of reboxetine and fluoxetine for treating major depres-
sion, focusing on the productivity improvements associ-
ated with each treatment. METHODS: A semi-Markov
model was constructed describing the course of depres-
sion and its treatment. The model combines efficacy data
from two head-to-head clinical trials of reboxetine and
fluoxetine with resource use estimates from expert opin-
ion elicited by questionnaire. Unit costs for resources
were obtained from the medical literature. The number
of disability days associated with each health state in the
model was estimated from population surveys and clini-
cal trial information. The model generated cost-effective-
ness measures for the total population as well as the sub-
set of severe patients (defined as patients with baseline
Clinical Global Impression severity scores of “markedly
ill”, “severely ill”, or “among the most extremely ill”) found
in the clinical trials. RESULTS: Model results showed no
significant differences in effectiveness between the two
treatment groups. For the total population, annual direct
medical and productivity costs totaled $6679 for rebox-
etine and $6958 for fluoxetine. Among severe patients,
total costs were $6946 for reboxetine and $7491 for flu-
oxetine. Productivity costs accounted for approximately
50% of the total cost of depression in both treatment
groups and patient populations. Sensitivity analyses con-
firmed the model’s robustness. CONCLUSIONS: The model
shows reboxetine to be cost saving compared to fluoxet-
ine for the treatment of major depression. The majority
of savings results from improvements in patient produc-
tivity, with the greatest potential for savings found in the
severe patient population. 
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OBJECTIVE: To compare the costs and quality of life of
77 patients who relapse with a control group of 68 non-
relapse patients, in schizophrenia. METHODS: Patients
were selected from current (active) psychiatric caseloads
drawn from urban, suburban and rural Leicester and Leices-
tershire. Relapse cases were identified by the re-emer-
gence and aggravation of symptoms, and by psychiatric
in-patient re-admissions, current or within the last 6 months.
Data collection included: social and demographic pro-
files, DSM IV classification, PANSS, CGI, GAF, Quality
of Life (Lehman), EuroQol, and health care utilization.
Standard parametric/non-parametric tests are used to test
for differences in outcomes and costs for relapse and
non-relapsing patients. Hypothesis-driven analyses focus
on the correlates of quality of life, links between symp-
toms and functioning, socio-economic consequences of
schizophrenia, and cost consequences of positive symp-
toms and functioning deficits. Standard multivariate analysis
will identify key determinants of costs, and Generalized
Linear Models will be used to predict relapse status. Pro-
visional results confirm higher costs and lower quality of
life for patients who relapse. CONCLUSIONS: Schizo-
phrenia is a long-term, debilitating and costly illness. Po-
tentially high costs are incurred by health care providers,
social services and other care agencies, and by families
and sufferers themselves. One of the most costly aspects
of schizophrenia is associated with illness relapse, which
has been estimated, for example, to cost $2 billion in re-
admission costs in the US. There is currently no equiva-
lent estimate for the UK. The findings from this study
will be of interest to policy-makers who face difficult eco-
nomic choices concerning new but more expensive drug
treatments for patients with schizophrenia. The challenge
for new antipyschotic treatments is to improve efficacy
and compliance and thereby reduce relapse rates. In turn
this would be expected to bring about reductions in the
total national costs of schizophrenia, whilst also improv-
ing the welfare of patients.
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OBJECTIVE: To assess utilization patterns, frequency of
side effects, and the cost of side effects associated with
